Dividendos de Rhinomed

Dividendo controles de criterios 0/6

Rhinomed no tiene antecedentes de pago de dividendos.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria	2.3%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	-AU$0.038
Rentabilidad por dividendo prevista a 3 años	n/a

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 10

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de RNO han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de RNO han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Rhinomed vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de RNO con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (RNO)	n/a
Suelo de mercado 25% (AU)	2.6%
Techo de mercado 25% (AU)	6.2%
Media de la industria (Pharmaceuticals)	2.3%
Previsión de analistas en 3 años (RNO)	n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de RNO en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de RNO en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de reparto de RNO para determinar si sus dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que RNO no ha comunicado ningún pago.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Dividendos de Rhinomed

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023

Full year 2023 earnings released: AU$0.038 loss per share (vs AU$0.02 loss in FY 2022)

Rhinomed Limited, Annual General Meeting, Nov 17, 2023

Full year 2023 earnings released: AU$0.039 loss per share (vs AU$0.02 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Market cap size

Insider recently bought AU$242k worth of stock

Insider recently bought AU$372k worth of stock

Is Rhinomed (ASX:RNO) Using Too Much Debt?

First half 2023 earnings released: AU$0.016 loss per share (vs AU$0.013 loss in 1H 2022)

Less than half of directors are independent

Rhinomed Limited, Annual General Meeting, Nov 18, 2022

Less than half of directors are independent

Rhinomed Limited Announces Rhinoswab Junior Study Confirms New Nasal Swab Is Most Accurate, Comfortable and Easy for Kids

Rhinomed Limited Appoints Lyn Swinburne AO as Non-Executive Director

Full year 2022 earnings released: AU$0.02 loss per share (vs AU$0.034 loss in FY 2021)

Rhinomed (ASX:RNO) Is In A Strong Position To Grow Its Business

Rhinomed Limited Announces the Interim Results in the World First "Rhinoswab for Diagnosis of Respiratory Virus in Children" Trial

CEO, MD & Executive Director exercised options to buy AU$855k worth of stock.

CEO, MD & Executive Director exercised options to buy AU$855k worth of stock.

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Here's Why We're Not Too Worried About Rhinomed's (ASX:RNO) Cash Burn Situation

Non-Executive Director recently bought AU$77k worth of stock

Non-Executive Director recently bought AU$76k worth of stock

Here's Why We're Watching Rhinomed's (ASX:RNO) Cash Burn Situation

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.034 loss in 1H 2020)

Key Things To Understand About Rhinomed's (ASX:RNO) CEO Pay Cheque

Independent Non-Executive Chairman recently bought AU$180k worth of stock

Insider recently bought AU$435k worth of stock

How Many Rhinomed Limited (ASX:RNO) Shares Did Insiders Buy, In The Last Year?

Rhinomed Limited Detects SARS-CoV-2 in Doherty Inst. RT-PCR Study

Rhinomed Limited Announces Registration of Nasal Swab with Australian Therapeutic Goods Administration

Rhinomed Limited Announces Registration of Its Novel Nasal Swab with the US FDA

Insider recently bought AU$513k worth of stock

Insider recently bought AU$443k worth of stock

Insider recently bought AU$668k worth of stock

Insider recently bought AU$600k worth of stock

Rhinomed Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.044 loss per share

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Discover strong dividend paying companies